NASDAQ:SMMT

Summit Therapeutics Competitors

$5.36
-0.24 (-4.29 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.36
Now: $5.36
$5.59
50-Day Range
$5.24
MA: $5.98
$6.97
52-Week Range
$2.90
Now: $5.36
$12.30
Volume140,515 shs
Average Volume207,734 shs
Market Capitalization$444.43 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87

Competitors

Summit Therapeutics (NASDAQ:SMMT) Vs. PAND, FPRX, CYTK, AMRX, IRWD, and SUPN

Should you be buying SMMT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Summit Therapeutics, including Pandion Therapeutics (PAND), Five Prime Therapeutics (FPRX), Cytokinetics (CYTK), Amneal Pharmaceuticals (AMRX), Ironwood Pharmaceuticals (IRWD), and Supernus Pharmaceuticals (SUPN).

Pandion Therapeutics (NASDAQ:PAND) and Summit Therapeutics (NASDAQ:SMMT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Pandion Therapeutics and Summit Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pandion Therapeutics02202.50
Summit Therapeutics01002.00

Pandion Therapeutics currently has a consensus price target of $44.25, indicating a potential downside of 26.31%. Summit Therapeutics has a consensus price target of $4.00, indicating a potential downside of 25.37%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Pandion Therapeutics.

Profitability

This table compares Pandion Therapeutics and Summit Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pandion TherapeuticsN/AN/AN/A
Summit Therapeutics-933.62%-100.94%-71.52%

Institutional and Insider Ownership

35.7% of Pandion Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Summit Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Pandion Therapeutics and Summit Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A
Summit Therapeutics$56.50 million7.87$9.99 millionN/AN/A

Summit Therapeutics has higher revenue and earnings than Pandion Therapeutics.

Summary

Pandion Therapeutics beats Summit Therapeutics on 7 of the 10 factors compared between the two stocks.

Summit Therapeutics (NASDAQ:SMMT) and Five Prime Therapeutics (NASDAQ:FPRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Volatility and Risk

Summit Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, meaning that its share price is 340% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Summit Therapeutics and Five Prime Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Summit Therapeutics01002.00
Five Prime Therapeutics06202.25

Summit Therapeutics presently has a consensus price target of $4.00, indicating a potential downside of 25.37%. Five Prime Therapeutics has a consensus price target of $30.7143, indicating a potential downside of 19.17%. Given Five Prime Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Five Prime Therapeutics is more favorable than Summit Therapeutics.

Profitability

This table compares Summit Therapeutics and Five Prime Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Summit Therapeutics-933.62%-100.94%-71.52%
Five Prime Therapeutics-554.71%-75.84%-49.08%

Institutional & Insider Ownership

9.5% of Summit Therapeutics shares are held by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are held by institutional investors. 6.4% of Five Prime Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Summit Therapeutics and Five Prime Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit Therapeutics$56.50 million7.87$9.99 millionN/AN/A
Five Prime Therapeutics$14.87 million119.01$-137,200,000.00($3.92)-9.69

Summit Therapeutics has higher revenue and earnings than Five Prime Therapeutics.

Summary

Five Prime Therapeutics beats Summit Therapeutics on 10 of the 12 factors compared between the two stocks.

Summit Therapeutics (NASDAQ:SMMT) and Cytokinetics (NASDAQ:CYTK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Volatility and Risk

Summit Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Summit Therapeutics and Cytokinetics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Summit Therapeutics01002.00
Cytokinetics011002.91

Summit Therapeutics presently has a consensus price target of $4.00, indicating a potential downside of 25.37%. Cytokinetics has a consensus price target of $33.6364, indicating a potential upside of 36.18%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts plainly believe Cytokinetics is more favorable than Summit Therapeutics.

Profitability

This table compares Summit Therapeutics and Cytokinetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Summit Therapeutics-933.62%-100.94%-71.52%
Cytokinetics-209.88%-3,065.14%-36.39%

Institutional & Insider Ownership

9.5% of Summit Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Cytokinetics shares are held by institutional investors. 6.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Summit Therapeutics and Cytokinetics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit Therapeutics$56.50 million7.87$9.99 millionN/AN/A
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71

Summit Therapeutics has higher revenue and earnings than Cytokinetics.

Summary

Cytokinetics beats Summit Therapeutics on 9 of the 12 factors compared between the two stocks.

Summit Therapeutics (NASDAQ:SMMT) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Earnings and Valuation

This table compares Summit Therapeutics and Amneal Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit Therapeutics$56.50 million7.87$9.99 millionN/AN/A
Amneal Pharmaceuticals$1.63 billion1.09$-361,920,000.00$0.2721.81

Summit Therapeutics has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Volatility & Risk

Summit Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Profitability

This table compares Summit Therapeutics and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Summit Therapeutics-933.62%-100.94%-71.52%
Amneal Pharmaceuticals3.30%42.02%3.82%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Summit Therapeutics and Amneal Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Summit Therapeutics01002.00
Amneal Pharmaceuticals01502.83

Summit Therapeutics presently has a consensus target price of $4.00, indicating a potential downside of 25.37%. Amneal Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 18.85%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Summit Therapeutics.

Institutional & Insider Ownership

9.5% of Summit Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Amneal Pharmaceuticals shares are held by institutional investors. 26.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats Summit Therapeutics on 10 of the 12 factors compared between the two stocks.

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Summit Therapeutics (NASDAQ:SMMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Valuation and Earnings

This table compares Ironwood Pharmaceuticals and Summit Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$428.41 million3.99$21.50 million$0.5519.29
Summit Therapeutics$56.50 million7.87$9.99 millionN/AN/A

Ironwood Pharmaceuticals has higher revenue and earnings than Summit Therapeutics.

Risk and Volatility

Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares Ironwood Pharmaceuticals and Summit Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ironwood Pharmaceuticals27.77%-240.80%27.05%
Summit Therapeutics-933.62%-100.94%-71.52%

Analyst Ratings

This is a breakdown of current ratings and target prices for Ironwood Pharmaceuticals and Summit Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ironwood Pharmaceuticals04102.20
Summit Therapeutics01002.00

Ironwood Pharmaceuticals currently has a consensus target price of $11.40, indicating a potential upside of 7.45%. Summit Therapeutics has a consensus target price of $4.00, indicating a potential downside of 25.37%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Ironwood Pharmaceuticals is more favorable than Summit Therapeutics.

Institutional and Insider Ownership

9.5% of Summit Therapeutics shares are held by institutional investors. 2.4% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Ironwood Pharmaceuticals beats Summit Therapeutics on 9 of the 12 factors compared between the two stocks.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Summit Therapeutics (NASDAQ:SMMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Valuation and Earnings

This table compares Supernus Pharmaceuticals and Summit Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$392.76 million4.27$113.06 million$2.1015.10
Summit Therapeutics$56.50 million7.87$9.99 millionN/AN/A

Supernus Pharmaceuticals has higher revenue and earnings than Summit Therapeutics.

Risk and Volatility

Supernus Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares Supernus Pharmaceuticals and Summit Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Supernus Pharmaceuticals27.09%20.02%9.67%
Summit Therapeutics-933.62%-100.94%-71.52%

Analyst Ratings

This is a breakdown of current ratings and target prices for Supernus Pharmaceuticals and Summit Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Supernus Pharmaceuticals00203.00
Summit Therapeutics01002.00

Supernus Pharmaceuticals currently has a consensus target price of $37.50, indicating a potential upside of 18.30%. Summit Therapeutics has a consensus target price of $4.00, indicating a potential downside of 25.37%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Supernus Pharmaceuticals is more favorable than Summit Therapeutics.

Institutional and Insider Ownership

96.1% of Supernus Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of Summit Therapeutics shares are held by institutional investors. 6.6% of Supernus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Supernus Pharmaceuticals beats Summit Therapeutics on 11 of the 12 factors compared between the two stocks.


Summit Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70-0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89-0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06-1.0%$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87-0.8%$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29-1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15-0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30-2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35-2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07-4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$27.37-5.6%$1.06 billionN/A0.00Increase in Short Interest
Lockup Expiration
News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.